SCHEMBL402930

SCHEMBL402930

CC(=O)OC1COC(C(=O)OCc2ccccc2)[C@@H](OCCCc2ccccc2)[C@H]1OCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BCHE P06276 3/20 0.41
KLK7 P49862 4/20 0.39
KLK5 Q9Y337 4/20 0.39
ALDH1A1 P00352 2/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ELANE P08246 3/20 0.37
CASP1 P29466 1/20 0.37
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
LMNA P02545 1/20 0.36
SLC6A2 P23975 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14362882 0.90 BCHE (0.46) BCHEKLK7KLK5ALDH1A1ELANE
SCHEMBL14362878 0.90 BCHE (0.46) BCHEKLK7KLK5ALDH1A1ELANE
SCHEMBL404205 0.85 MEN1 (0.37) BCHEKLK7KLK5ALDH1A1MEN1
SCHEMBL404381 0.84 LMNA (0.42) ALDH1A1MEN1KMT2ACASP1POLB
SCHEMBL402317 0.84 BCHE (0.45) BCHEKLK7KLK5ALDH1A1ELANE
SCHEMBL403707 0.84 BCHE (0.45) BCHEKLK7KLK5ALDH1A1ELANE
SCHEMBL403099 0.84 BCHE (0.43) BCHEKLK7KLK5MEN1KMT2A
SCHEMBL402527 0.78 BCHE (0.45) BCHEKLK7KLK5ALDH1A1ELANE
SCHEMBL403509 0.78 BCHE (0.45) BCHEKLK7KLK5ALDH1A1ELANE
SCHEMBL14363014 0.78 BCHE (0.38) BCHEKLK7KLK5ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065153-A1 AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF SANOFI-AVENTIS (FR) 2012-03-15 US disclosed
US-20070270354-A1 Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof SANOFI-AVENTIS (FR) 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065153-A1 AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF HPSE, HAAO, HEXD BCHE 1419/4885KLK7 1399/4885KLK5 1277/4885
US-20070270354-A1 Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof HPSE, HAAO, HEXD BCHE 1409/4885KLK7 1402/4885KLK5 1250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.